Halozyme director sells 1,625 shares under plan

HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported open-market sales of a total of 1,625 shares of common stock.

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported open-market sales of a total of 1,625 shares of common stock. The trades were executed at weighted average prices of about $76 to $77 per share across two price ranges.

The sales were made under a pre-arranged written trading plan adopted on May 29, 2025 in accordance with Rule 10b5-1, indicating these transactions were scheduled in advance as part of ongoing portfolio management rather than discretionary timing decisions.

Insider Trade Summary 10b5-1

Net Seller: 1,625 shares

Net Sell 2 txns

Insider Connaughton Bernadette

Role Director

Sold 1,625 shs ($125K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,000	$76.395	$76K
Sale	Common Stock	625	$77.209	$48K

Holdings After Transaction: Common Stock — 42,044 shares (Direct)

Footnotes (3)

1. F1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.
2. F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.930 to $76.850. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.950 to $77.710. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Key Figures

Shares sold: 1,625 shares Weighted average price 1: $76.395/share Weighted average price 2: $77.209/share +2 more

5 metrics

Shares sold 1,625 shares Total common stock sold in two transactions

Weighted average price 1 $76.395/share First sale tranche weighted average price

Weighted average price 2 $77.209/share Second sale tranche weighted average price

Price range tranche 1 $75.930–$76.850 Range of individual trade prices in first tranche

Price range tranche 2 $76.950–$77.710 Range of individual trade prices in second tranche

Key Terms

Rule 10b5-1, weighted average sales price per share, open-market sale

3 terms

Rule 10b5-1 regulatory

"written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average sales price per share financial

"Represents a weighted average sales price per share. The shares were sold at prices ranging from"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HALOZYME (HALO) shares did Bernadette Connaughton sell?

Bernadette Connaughton sold a total of 1,625 shares of HALOZYME common stock. The Form 4 shows two open-market sale transactions on the same date that together sum to this amount, reflecting a relatively small director trade.

At what prices were the HALOZYME (HALO) shares sold by the director?

The reported sales used weighted average prices of $76.395 and $77.209 per share. Footnotes explain that actual trade prices ranged from $75.930 to $77.710 across the executed transactions, with full price breakdowns available on request.

Were the HALOZYME (HALO) insider sales made under a 10b5-1 trading plan?

Yes. The filing states the sales were made under a written Rule 10b5-1 trading plan adopted on May 29, 2025. Such plans pre-schedule trades, reducing the significance of day-to-day market timing decisions by the reporting person.

What type of transactions did the HALOZYME (HALO) Form 4 report?

The Form 4 reports two open-market sale transactions in HALOZYME common stock, both coded “S” for sale. These are non-derivative trades, meaning they involve direct share sales rather than options or other derivative securities.

Does the HALOZYME (HALO) director still hold shares after these sales?

The Form 4 indicates the director continues to hold HALOZYME common stock after the transactions. Exact post-transaction holdings are shown in the filing’s share-balance fields for each line item, demonstrating the sales represent only a portion of her position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Connaughton Bernadette

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		1,000	D	$76.395(2)	42,669	D
Common Stock	07/01/2026		S(1)		625	D	$77.209(3)	42,044	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.930 to $76.850. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.950 to $77.710. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)